Soleus Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Soleus Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-31,136	Closed	-$870K	–	79
2021 Q1	$870K	Hold	31,136	–	–	0.16%	68
2020 Q4	$882K	Sell	31,136 -10,481	-25%	-$271K	0.12%	55
2020 Q3	$1.05M	Buy	41,617 +13,148	+46%	+$345K	0.55%	41
2020 Q2	$695K	Buy	28,469 +16,600	+140%	+$328K	0.4%	48
2020 Q1	$176K	Sell	11,869 -11,331	-49%	-$234K	0.2%	46
2019 Q4	$376K	Buy	+23,200	New	+$360K	0.36%	42

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Soleus Capital Management's RVNC Position: Q2 2021 in Review

Soleus Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2021, closing a stake of 31,136 shares — an estimated $870K sold.

Soleus Capital Management first reported a position in RVNC in Q4 2019 and held it in 6 quarters. The position peaked at $1.05M in Q3 2020. 161 funds tracked by Wall St. Rank hold RVNC as of Q2 2021.

Soleus Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Soleus Capital Management sold 31,136 Revance Therapeutics, Inc. shares in Q2 2021, an estimated $870K.
Soleus Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2019 and held it in 6 quarters.
Soleus Capital Management's Revance Therapeutics, Inc. position peaked at $1.05M in Q3 2020.
161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2021.

Based on Soleus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.